Abstract：
OBJECTIVE: Trichorhinophalangeal syndrome-1 (TRPS1) has been proposed as a novel breast marker with equally high expression in breast cancer (BC) subtypes, making it a useful diagnostic tool. Here, its expression was evaluated alongside other commonly used markers [GATA3, GCDFP15, mammaglobin (MGB) and SOX10] in a large cohort of BCs (n = 1852) and their corresponding nodal metastases. Its usefulness as a diagnostic tool and its correlation with clinicopathological features were assessed.
RESULTS: TRPS1 was expressed at 75.8% overall in the BC cohort, with at least 58% expression among BC subtypes. It was less sensitive than GATA3 for luminal and HER2-overexpressing (HER2-OE) cancers (luminal A: 82 versus 97%; luminal B: 80 versus 95%; HER2-OE: 62 versus 76%), but it was the most sensitive for TNBC (60 versus ≤ 41%). It showed a stable expression in nodal metastases (primary tumour 76 versus nodal metastasis 78%), unlike a reduced nodal expression for GATA3 (86 versus 77%). TRPS1 outperformed GATA3 in detecting non-luminal cancers when paired with other breast markers. TRPS1 and GCDFP15 was the most sensitive combination in TNBC detection, with a 76% detection rate. For TRPS1-negative and GCDFP15-negative TNBCs, SOX10 was more sensitive than GATA3 (29 versus 24%).
CONCLUSIONS: TRPS1 is a highly sensitive marker for all breast cancer subtypes, outperforming GATA3 in non-luminal cancers and displaying the highest sensitivity for TNBC detection when combined with GCDFP15. It is a valuable addition to the breast marker panel for accurate identification of BC.
RESULTS: TRPS1 was expressed at 75.8% overall in the BC cohort, with at least 58% expression among BC subtypes. It was less sensitive than GATA3 for luminal and HER2-overexpressing (HER2-OE) cancers (luminal A: 82 versus 97%; luminal B: 80 versus 95%; HER2-OE: 62 versus 76%), but it was the most sensitive for TNBC (60 versus ≤ 41%). It showed a stable expression in nodal metastases (primary tumour 76 versus nodal metastasis 78%), unlike a reduced nodal expression for GATA3 (86 versus 77%). TRPS1 outperformed GATA3 in detecting non-luminal cancers when paired with other breast markers. TRPS1 and GCDFP15 was the most sensitive combination in TNBC detection, with a 76% detection rate. For TRPS1-negative and GCDFP15-negative TNBCs, SOX10 was more sensitive than GATA3 (29 versus 24%).
CONCLUSIONS: TRPS1 is a highly sensitive marker for all breast cancer subtypes, outperforming GATA3 in non-luminal cancers and displaying the highest sensitivity for TNBC detection when combined with GCDFP15. It is a valuable addition to the breast marker panel for accurate identification of BC.
摘要：
目的：Tricho-halinophalangeinsyndrome-1(TRPS1)已被提出作为一种新的乳腺标志物，在乳腺癌(BC)亚型中同样高表达。使其成为有用的诊断工具。这里,在大量BCs(n=1852)及其相应的淋巴结转移中,与其他常用标志物[GATA3,GCDFP15,乳腺球蛋白(MGB)和SOX10]一起评估其表达.评估了其作为诊断工具的有用性及其与临床病理特征的相关性。
结果：TRPS1在BC队列中总体表达为75.8％，在BC亚型中至少有58%的表达。它对管腔和HER2过表达（HER2-OE）癌症的敏感性低于GATA3（管腔A：82对97％；管腔B：80对95％；HER2-OE：62对76％），但对TNBC最敏感(60对≤41%)。它在淋巴结转移中显示出稳定的表达（原发性肿瘤76与淋巴结转移78％），与GATA3的淋巴结表达减少不同（86对77％）。当与其他乳腺标记物配对时，TRPS1在检测非腔癌方面优于GATA3。TRPS1和GCDFP15是TNBC检测中最敏感的组合，检出率为76%。对于TRPS1阴性和GCDFP15阴性TNBC，SOX10比GATA3更敏感(29%对24%)。
结论：TRPS1是所有乳腺癌亚型的高度敏感标志物，在非管腔癌症中优于GATA3，并且当与GCDFP15组合时显示对TNBC检测的最高灵敏度。它是一个有价值的补充，以准确识别BC的乳房标记面板。
结果：TRPS1在BC队列中总体表达为75.8％，在BC亚型中至少有58%的表达。它对管腔和HER2过表达（HER2-OE）癌症的敏感性低于GATA3（管腔A：82对97％；管腔B：80对95％；HER2-OE：62对76％），但对TNBC最敏感(60对≤41%)。它在淋巴结转移中显示出稳定的表达（原发性肿瘤76与淋巴结转移78％），与GATA3的淋巴结表达减少不同（86对77％）。当与其他乳腺标记物配对时，TRPS1在检测非腔癌方面优于GATA3。TRPS1和GCDFP15是TNBC检测中最敏感的组合，检出率为76%。对于TRPS1阴性和GCDFP15阴性TNBC，SOX10比GATA3更敏感(29%对24%)。
结论：TRPS1是所有乳腺癌亚型的高度敏感标志物，在非管腔癌症中优于GATA3，并且当与GCDFP15组合时显示对TNBC检测的最高灵敏度。它是一个有价值的补充，以准确识别BC的乳房标记面板。
